The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.80
Bid: 17.42
Ask: 17.80
Change: -0.49 (-2.71%)
Spread: 0.38 (2.181%)
Open: 17.64
High: 17.80
Low: 17.60
Prev. Close: 18.10
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

First Day of Dealings on the Main Market

1 May 2015 08:00

RNS Number : 9426L
Nanoco Group PLC
01 May 2015
 

 

For immediate release

1 May 2015

 

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company")

 

First Day of Dealings on the Main Market

and Completion of Placing to raise £20 million gross

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, is pleased to announce the commencement of trading in its ordinary shares at 8.00am today on the Main Market of the London Stock Exchange and admission to the premium segment of the Official List of the UK Listing Authority. The commencement of trading on the Main Market is simultaneous with the cancellation of the Company's shares on AIM.

 

The commencement of trading on the Main Market is the final condition for the completion of the Placing, initially announced on 31 March 2015, of 19,047,619 new ordinary shares at a price of 105 pence each, raising gross proceeds of £20 million.

 

Highlights

 

· The net proceeds of the Placing of £18.65 million will enable Nanoco to fund its Business Expansion Strategy of accelerated research, development and commercialisation in its four key target markets - electronic display, LED lighting, solar power and biological imaging.

 

· Use of the proceeds are planned to include:

 

- Improved working capital to support increased capacity and continued optimisation of Nanoco's CFQD® quantum dot production processes

 

- Hiring additional research and development staff and enhancing the senior management structure to re-organise the business into four distinct business divisions, reflecting the key target markets

 

- Broadening the Company's research capabilities in solar through the appointment of a specialist solar panel manufacturer to prove Nanoco's technology on larger solar panels

 

- Investment in laboratory space and the enhancement of the Company's intellectual property portfolio

 

· The transition from AIM to the Main Market is expected to provide a more appropriate platform for the continued growth of the business, raise its profile and improve the trading liquidity of the Company's shares

 

· As previously announced, Robin Williams, a Non-executive Director of Nanoco, through his SIPP, subscribed for 9,523 ordinary shares in the Placing at 105 pence per share. Therefore, on Admission, Robin is interested in of 9,532 ordinary shares, representing to 0.004% of the enlarged issued share capital of the Company

 

Michael Edelman, Nanoco's Chief Executive Officer, commented: "Nanoco's transition from AIM to the Main Market comes at an exciting point in the Company's development and marks an important step in the Company's evolution towards its goal of becoming a leading, global materials science business.

 

"I would like to thank the new and existing investors who subscribed for shares in the Placing which accompanied our move to the Main Market. The proceeds from the Placing will allow us to accelerate the commercialisation of our technology through the funding of further R&D and through the formation of four distinct business divisions focused on our key target markets of electronic display, LED lighting, solar power and biological imaging.

 

"We are very excited by our commercial progress in the display market. We expect, the first LCD TVs to incorporate our technology to be launched in the near future and our worldwide licensing partner Dow is close to commissioning its mass production plant in South Korea, where Nanoco quantum dots will be manufactured in much larger quantities."

 

Total voting rights

 

The total number of ordinary shares in the Company immediately following admission, including the New Ordinary Shares, is 236,378,002 each with equal voting rights. This total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in the Company under the Disclosure and Transparency Rules of the Financial Conduct Authority.

 

 

All capitalised terms in this announcement have the meaning given to them in the Circular posted to shareholders on 31 March 2015. The Circular, and the Prospectus, are available at the investor relations section of Nanoco's website, www.nanocotechnologies.com.

 

 

For further information, please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

 

Mark Sullivan, Interim Chief Financial Officer

 

 

 

Canaccord Genuity - Sponsor and Joint Broker

Tel: +44 (0) 20 7523 8000

Simon Bridges

 

Cameron Duncan

Mark Whitmore

 

 

 

Liberum - Joint Broker

Tel: +44 (0) 20 3100 2000

Simon Atkinson

 

Richard Bootle

 

 

 

Buchanan

Tel: +44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Stephanie Watson

 

 

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRGDSDXXBGUG
Date   Source Headline
2nd Aug 20237:00 amRNSISS recommendation to support Nanoco’s Board
1st Aug 20237:13 amRNSTotal Voting Rights
28th Jul 20235:23 pmRNSDirector/PDMR Shareholding
25th Jul 20232:55 pmRNSPublication of Shareholder Presentation
25th Jul 202312:52 pmRNSNanoco Group Plc
24th Jul 20237:00 amRNSHigh Court Confirmation of Capital Reduction
20th Jul 20237:00 amRNSNotification of Investor Presentation
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting
7th Jul 202311:23 amRNSGeneral Meeting - Voting Results
28th Jun 20237:00 amRNSReceipt of General Meeting Requisition Notice
20th Jun 20237:00 amRNSPosting of Circular and Notice of General Meeting
9th Jun 20237:00 amRNSBlocklisting Six-Monthly Return
19th May 20231:00 pmRNSResponse to Shareholder Letter
21st Apr 20236:00 pmRNSHolding(s) in Company
30th Mar 202311:46 amRNSHolding(s) in Company
28th Mar 20237:00 amRNSInterim Results
27th Mar 20231:19 pmRNSResponse to Shareholder Letter
23rd Mar 20238:40 amRNSNotice of Results
9th Mar 20233:11 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSHolding(s) in Company
3rd Feb 20237:15 amRNSTrading Update
3rd Feb 20237:15 amRNSLitigation Settlement Update
18th Jan 202311:35 amRNSHolding(s) in Company
16th Jan 202312:45 pmRNSHolding(s) in Company
11th Jan 20232:40 pmRNSHolding(s) in Company
10th Jan 20232:37 pmRNSHolding(s) in Company
9th Jan 20237:00 amRNSLitigation Settlement Update
6th Jan 20237:00 amRNSLitigation Outcome – Settlement Agreed
4th Jan 20233:31 pmRNSHolding(s) in Company
20th Dec 20223:51 pmRNSHolding(s) in Company
20th Dec 20222:59 pmRNSResult of AGM
20th Dec 20227:00 amRNSAGM Statement
13th Dec 20227:00 amRNSBlock listing Six-monthly Return
9th Dec 20227:00 amRNSLitigation Update - Firm Trial Date
14th Nov 202210:46 amRNS2022 Annual Report and Notice of AGM
7th Nov 20224:13 pmRNSHolding(s) in Company
27th Oct 20225:19 pmRNSDirector/PDMR Shareholding
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.